Don’t Let
Non-Adherence
Undermine Control:
Are You Doing
Enough to Protect
Your Patients?
Average BP reduction SPC vs FEC3
SPCs improves BP goal achievement rate by 34-53% (vs monotherapy and FEC)4
Exforge® reduces the risk of peripheral edema by 38% compared to amlodipine (relative risk reduction)2
Exforge® has 70% less increase in ankle and foot volume compared with amlodipine3
Powerful control, for every patient
24-hour protection that lasts
Proven to safeguard heart and kidneys
One pill, guideline-recommended
Footnote
a) Use of Diuretics: Consider transition to Loop Diuretic if eGFR is between 30 to 45 ml/min/1.73 m2. If eGFR <30 ml/min/1.73 m2 use Loop Diuretic.
(b) Non-DHP CCB should not be combined with BB.
(c) BB should be used as guideline directed medical therapy in respective indications or considered in several other conditions. Start with dual combination therapy including a RAS-blocker (either ACEi or ARB) plus a T/TLDiuretic or a CCB is recommended (thick blue lines).
Abbreviations
BP, Blood Pressure; CAD, Coronary Artery Disease; CI, Confidence Interval; CV, Cardiovascular; ESC, European Society of Cardiology; ESH, European Society of Hypertension; HR, Hazard Ratio; HTN, Hypertension; MI, Myocardial Infarction; RCT, Randomized Controlled Trial; SBP, Systolic Blood Pressure; SPC, Single-Pill Combination; TIA, Transient Ischemic Attack;
References
1. McEvoy JW, et al. Eur Heart J. 2024;45(38):3912–4018. 2. Mancia G, et al. J Hypertens. 2023;41(12):1874–2071. 3. Parati G, et al. Hypertension. 2021;77(2):692–705. 4. Egan BM, et al. Hypertension. 2012;59(6):1124–1131. 5. Tsioufis K, et al. J Hypertens. 2020;38(6):1016–1028. 6. Weisser B, et al. Eur Heart J Cardiovasc PharmacoTher. 2025;10(8):686–693. 7. Coca A, et al. Eur J Intern Med. 2024;126:16–25. 8. Hu D, et al. Adv Ther. 2014;31(7):762–75. 9. Kızılırmak P, et al. Turk Kardiyol Dern Ars. 2013;41(5):406–417. 10. Makani H, et al. Am J Med. 2011;124(2):128–135. 11. Pool JL, et al. Clin Ther. 2007;29(1):61–73. 12. Pfeffer MA et al. for the Valsartan in Acute Myocardial Infarction Trial Investigators. N Engl J Med. 2003;349(20):1893–1906. 13. Cohn JN et al. for the Valsartan Heart Failure Trial Investigators. N Engl J Med. 2001;345(23):1667–1675. 14. Viberti G et al. Circulation. 2002;106(6):672–678. 15. Julius S et al. Lancet. 2004;363(9426):2022–2031. 16. The NAVIGATOR study group. N Engl J Med. 2010;362:1477–90.
20 Pasir Panjang Road #10-25/28 Mapletree Business City (West Tower) Singapore 117439
Phone: +65 6722 6010
FOR HEALTHCARE PROFESSIONALS ONLY
APPROVAL CODE
